Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer and its relations to the micrometastasis in peripheral blood

Abstract

To examine the relationship between the levels of the serum vascular endothelial growth factor (VEGF) and the micrometastasis of peripheral blood in patients with non-small cell lung cancer (NSCLC), 108 NSCLC patients, including 40 patients with benign lung diseases and 30 healthy controls, were investigated. The serum VEGF levels were detected by ELISA and CK19 mRNA in peripheral blood by reverse transcriptase-polymerase chain reaction (RT-PCR). In NSCLC group, the serum VEGF levels and the positive rate of CK19 mRNA in peripheral blood were 479.8±268.5 pg/mL and 66.7%, which were significantly higher than those of the other two groups respectively (P<0.01), and both of them were increased significantly with the progression of clinical stage of the tumors (P<0.01). Serum VEGF levels as well as the positive rate of CK19 mRNA in different pathological types of lung cancer had no significant differences (P>0.05). Serum VEGF levels in the patients positive for CK19 mRNA was 561.7±325.6 pg/mL. It is significantly higher than that in the negative patients (P<0.01). There existed a significant correlation between serum VEGF levels and expression of CK19 mRNA in peripheral blood in NSCLC patients (P<0.001). The detection of serum VEGF levels and CK19 mRNA in peripheral blood is helpful in judging the condition and the prognosis of NSCLC patients, and serum VEGF levels and CK19 mRNA are independent of the pathological types of lung cancer. The micrometastasis in peripheral blood of NSCLC patients is significantly associated with serum VEGF levels.

Keywords

lung neoplasm / vascular endothelial growth factor (VEGF) / micrometastasis / cytokeratin 19

References

[1] OsakiT., OyamaT., InoueM., et al.. Molecular biological markers, an micrometastasis in resected non-small cell lung cancer. Prognostic implications. Jap J Thorac Cardiovasc Surg, 2001, 49(9): 545-541

[2] JiaoX., KrasnaM.J.. Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg, 2002, 74(1): 278-284

[3] Le Pimpec-BarthesF., DanelC., LacaveR., et al.. Association of CK19 mRNA detection of occult cancer cells in mediastinal lymph nodes in non-small cell lung carcinoma and high risk of early recurrence. Eur J Cancer, 2005, 41(2): 306-312

[4] BuccheriG., FerrignoD.. Cytokeratin-derived markers of lung cancer. Expert Rev Mol Diagn, 2001, 1(3): 315-322

[5] TakahashiY., KitadaiY., BucanaC.D., et al.. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res, 1995, 55(18): 3964-3968

[6] DvorakH.F., NagyJ.A., FengD., et al.. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol, 1999, 237: 97-132

[7] FolkmanJ.. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst, 1990, 82(1): 4-6

[8] QuZ., Van GinkelS., RoyA.M., et al.. Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res, 2008, 68(15): 6232-6240

[9] ShibuyaM.. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep, 2008, 41(4): 278-286

[10] HoschS.B., ScheunemannP., IzbickiJ.R.. Minimal residual disease in non-small-cell lung cancer. Semin Surg Oncol, 2001, 20(4): 278-281

[11] SaadA.G., YeapB.Y., ThunnissenF.B., et al.. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer, 2008, 113(8): 2129-2138

[12] AchenM.G., StackerS.A.. Molecular control of lymphatic metastasis. Ann N Y Acad Sci, 2008, 1131: 225-234

[13] DemirkazikA., AkbulutH., UlgerA.F., et al.. Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer. Ann Saudi Med, 2004, 24(6): 473-475

[14] FutamiR., MiyashitaM., NomuraT., et al.. Increased serum vascular endothelial growth factor following major surgical injury. J Nippon Med Sch, 2007, 74(3): 223-229

[15] AitaM., FasolaG., DefferrariC., et al.. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol, 2008, 68(3): 183-196

[16] Katsabeki-KatsafliA., KerenidiT., KostikasK., et al.. Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. Lung Cancer, 2008, 60(2): 271-276

[17] HoldenriederS., StieberP., von PawelJ., et al.. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res, 2004, 10(18Pt1): 5981-5987

[18] ChengM., ChenY., YuX., et al.. Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer, 2008, 8: 156

[19] GeM.J., WuQ.C., WangM., et al.. Detection of disseminated lung cancer cells in regional lymph nodes by assay of CK19 reverse transcriptase polymerase chain reaction and its clinical significance. J Cancer Res Clin Oncol, 2005, 131(10): 662-668

[20] SaintgnyP., CoulonS., KambouchnerM., et al.. Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for diagnosis of lymph node micrometastases in non small cell lung carcinoma. Int J Cancer, 2005, 115(5): 777-782

[21] Kasimir-BauerS., SchleucherN., WeberR., et al.. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. Oncol Rep, 2003, 10(2): 475-482

[22] HuangC., LiuD., MasuyaD., et al.. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer, 2005, 92(7): 1231-1239

[23] DongQ., FengJ., HuangJ., et al.. Vascular endothelial growth factor promotes hematogenous metastasis of cancer cells in patients with non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi (Chinese), 2002, 24(2): 142-146

[24] NishiM., AbeY., TomiiY., et al.. Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int J Oncol, 2005, 26(6): 1517-1524

[25] BruecklW.M., SchoeberlA., WirtzR.M., et al.. Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). J Thorac Oncol, 2008, 3(3): 314-316

[26] KeedyV.L., SandlerA.B.. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci, 2007, 98(12): 1825-1830